Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2016
Price : $35 *
At a glance
- Drugs CRS 3123 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- 09 Jun 2016 Status changed from recruiting to completed.
- 02 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 according to ClinicalTrials.gov record.
- 02 Oct 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.